Medexus Pharmaceuticals Inc.
MEDXF
$2.05
-$0.03-1.44%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 105.66M | 108.33M | 109.54M | 104.76M | 108.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.66M | 108.33M | 109.54M | 104.76M | 108.78M |
| Cost of Revenue | 42.21M | 44.82M | 46.13M | 44.15M | 46.15M |
| Gross Profit | 63.45M | 63.51M | 63.41M | 60.61M | 62.63M |
| SG&A Expenses | 45.00M | 43.18M | 41.38M | 41.10M | 43.32M |
| Depreciation & Amortization | 8.19M | 7.18M | 6.19M | 5.88M | 5.77M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.22M | 96.41M | 94.50M | 91.94M | 96.51M |
| Operating Income | 8.44M | 11.92M | 15.04M | 12.82M | 12.28M |
| Income Before Tax | 155.00K | 1.44M | 3.19M | 1.51M | 1.12M |
| Income Tax Expenses | -651.00K | -807.00K | -373.00K | -781.00K | 30.00K |
| Earnings from Continuing Operations | 0.81 | 2.25 | 3.56 | 2.30 | 1.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 806.00K | 2.25M | 3.56M | 2.30M | 1.09M |
| EBIT | 8.44M | 11.92M | 15.04M | 12.82M | 12.28M |
| EBITDA | 16.59M | 19.06M | 21.08M | 18.56M | 17.90M |
| EPS Basic | 0.03 | 0.10 | 0.15 | 0.09 | 0.04 |
| Normalized Basic EPS | 0.07 | 0.13 | 0.20 | 0.16 | 0.08 |
| EPS Diluted | 0.03 | 0.10 | 0.15 | 0.09 | 0.04 |
| Normalized Diluted EPS | 0.07 | 0.13 | 0.20 | 0.16 | 0.08 |
| Average Basic Shares Outstanding | 111.09M | 103.29M | 98.13M | 97.64M | 93.53M |
| Average Diluted Shares Outstanding | 111.09M | 103.29M | 98.13M | 97.64M | 93.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |